Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb:56:52-60.
doi: 10.1016/j.coph.2020.10.021. Epub 2020 Dec 10.

Prospects for severe asthma treatment

Luigino Calzetta  1 , Maria Gabriella Matera  2 , Angelo Coppola  3 , Paola Rogliani  4
Affiliations
Review

Prospects for severe asthma treatment

Luigino Calzetta et al. Curr Opin Pharmacol. 2021 Feb.

Abstract

Biological drugs are approved to treat patients with severe uncontrolled asthma and are directed against mediators of type 2 immunity. These agents are effective in reducing the risk of exacerbation, maintaining asthma symptom control and reducing the need of systemic corticosteroids. Although biological drugs have revolutionized the management of the disease, to date there are no head-to-head studies across the current available molecules and there remains the need of specific biomarkers for the diagnosis, prognosis and response to treatment. Moreover, there is still an urgent need to identify further molecular targets to offer effective treatments for those patients who are not responsive to the currently available biological drugs, by moving upstream in the inflammatory cascade to inhibit multiple inflammatory pathways and/or identify effective nontype 2 immunity mechanisms.

Keywords: Biologics; Biomarkers; Inflammation; Monoclonal antibodies; Severe asthma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement LC has participated as advisor in scientific meetings under the sponsorship of Boehringer Ingelheim and Novartis, received nonfinancial support from AstraZeneca, a research grant partially funded by Chiesi Farmaceutici, Boehringer Ingelheim, Novartis, and Almirall, and is or has been a consultant to ABC Farmaceutici, Edmond Pharma, Zambon, Verona Pharma, and Ockham Biotech. His department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, Zambon. MGM has participated as a lecturer, speaker and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline and Novartis and has been a consultant to ABC Farmaceutici, Chiesi Farmaceutici. Her department was funded by Novartis. AC participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Menarini Group and Zambon. PR participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis; and her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici Novartis, and Zambon.